A global top 20 consumer and pharmaceutical company with offices in Japan, offering innovative, science-based medicinal products approached Freyr for support in collating and transforming XEVMPD data to IDMP data for large number of Market Authorization submissions. Achieving 1500 MAs within a short period of time and lack of internal software at client’s place stood as a challenging factor for this project.
Through this report you can get insights on how Freyr performed comprehensive risk analysis and been conversant with IDMP requirements and data sources for the America, Japan and Europe regions
Fill the form below to download the Case Study
